日本人白血病またはリンパ腫患者におけるネララビン（506U78）の臨床評価

基本情報

NCT ID

NCT00406757

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

13

治験依頼者名

GlaxoSmithKline

概要

In Japan, patients with relapsed or refractory T-ALL/T-LBL represent an extremely small patient population. While the small number of patients presents a practical limitation to the size of a clinical trial, patients whose disease has not responded to or has relapsed after treatment with multiple prior chemotherapy regimens have no accepted standard therapies available. Japanese leukemia experts have expressed interest in evaluating 506U78 in Japanese patients with relapsed or refractory T-ALL/T-LBL. In order to obtain safety, tolerability, and pharmacokinetic data of 506U78 in Japanese patients, this study is designed to maximize the contribution of each available patient.

対象疾患

介入

依頼者（Sponsor）